AI pharmaceuticals are different from traditional pharmaceuticals and are expected to break the dilemma that the average cost of new drug research and development exceeds US$1 billion and the R&D cycle is greater than 10 years, so it is highly expected
by the industry.
In China, in recent years, with the promotion of relevant policies such as centralized procurement and medical insurance, pharmaceutical companies have come under obvious pressure, and it is urgent to reduce the time and cost of new drug research and development and reduce the probability of
failure.
AI Pharma is regarded as a breakthrough in the research and development of innovative drugs, and it continues to be hot
in China.
According to the "2022 AI Pharmaceutical Industry Observation Report" (hereinafter referred to as the "Report") released by Insilico during the 2022 Shanghai International Biomedical Industry Week, according to incomplete statistics, in 2021, more than 20 domestic AI pharmaceutical companies have obtained nearly 10 billion yuan in financing, involving Insilico, Wangshi Intelligence, XtalPi, Xingyao Technology, Bingzhoushi, Xingqi Biotechnology, Finkun Intelligent Unknown Jun, Derui Zhi Pharmaceutical and other enterprises
.
Many single financings exceeded 100 million US dollars, for example, Unknown Jun completed nearly 100 million US dollars in Series B financing, Insilico completed 255 million US dollars in Series C financing, and XtalPi announced the completion of 400 million US dollars in Series D financing.
.
.
Chinese smart drug development companies are on the rise
.
Round after round of financing AI pharmaceuticals has attracted many pharmaceutical companies and even cross-border companies, including technology head companies, to actively deploy this track
.
For example, Huawei has established the medical intelligent twin "EIHealth", and Baidu and Tencent have established the Baitu Biotech and Yunshen pharmaceutical platforms to quickly enter the game using their accumulated AI algorithm experience.
Ali quickly established upstream and downstream relationships with its advantages in computing power; ByteDance has established an aurora department dedicated to the big health business, and has recruited AI-drug teams at home and abroad
.
Pharmaceutical companies with drug research and development experience have established AI pharmaceutical R&D teams on this basis, such as AstraZeneca, Merck, Pfizer and Teva, and have jointly established AION Labs laboratories with Amazon and Israel Biofund
.
Since 2022, many domestic pharmaceutical companies have also laid out the AI pharmaceutical field
.
For example, in January this year, Insilico and Fosun Pharma jointly announced a cooperation agreement to jointly promote the research and development
of AI drugs in multiple targets on a global scale.
Under the agreement, Insilico will receive a down payment of $13 million, a milestone payment, and share in the commercialization profits
of the QPCTL project.
In addition, Fosun Pharma will provide equity investment
to Insilico.
On July 25, Yunnan Baiyao announced that the company and Huawei Technologies signed the "Comprehensive Cooperation Agreement on Artificial Intelligence Drug R&D" on July 23, and the two sides explored the mechanism of joint scientific research and innovation, carried out extensive exchanges and cooperation in the field of AI and drug research and development, and expanded the breadth and depth
of cooperation between the two sides.
Including but not limited to large and small molecule design, related diseases, database development, etc
.
On November 12, Insilico announced that the company reached a drug research and development cooperation
with the multinational pharmaceutical company Sanofi.
Under the agreement, Sanofi will be required to pay Insilico an aggregate upfront payment and target discovery costs of up to US$21.
5 million, additional R&D and commercial milestone payments, with a total potential value of up to US$1.
2 billion.
At the same time, Sanofi will promote the development
of drug candidates based on no more than 6 innovative targets through Insilico's intelligent AI drug discovery platform and a team of drug discovery scientists.
The industry conservatively estimates that the domestic AI pharmaceutical market will reach 204 billion yuan
.
It is worth mentioning that although there are many players in the current layout, there is not a drug successfully developed by AI in the world, and most of the AI drugs of the layout company are in the clinical phase I stage, so whether these drugs can be completed in the future is not guaranteed
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
